Abstract: The present invention relates to bendamustine derivatives and related compounds of formula (VII), (VIII) and (IX), and medical uses thereof in particular in cancer therapy.

Abstract: This disclosure relates to the release of singlet oxygen by thermally activated decomposition of aromatic endoperoxide molecules in material systems [e.g. polymer (nano)particles or polymer films]. Due to the short lifespan and diffusion length of singlet oxygen, the technical problem is that the majority of the decomposition may only take place if the singlet oxygen molecules can reach the target region. For example, either the penetration of the polymer particles into the cancer cells to be killed, or the settlement of bacteria on an implant coated with the polymer film, must be accomplished. It is necessary to allow adaptation of the time progression of the decomposition for the application. The adaptation is performed by chemically and/or physically modifying the functional structures present in the material system, each made of the molecule forming the endoperoxide and at least one adjacent molecule or the cage formed by all adjacent molecules.

Abstract: The present invention relates to bendamustine derivatives and related compounds of formula (VII), (VIII) and (IX), and medical uses thereof in particular in cancer therapy.

Abstract: The present invention relates to particular esters of bendamustine and related compounds, and medical uses thereof.

Abstract: The present invention relates to diester prodrugs of cilazaprilate which undergo enzymatic cleavage to release the active metabolite cilazaprilate that is used for the treatment of hypertension and congestive heart failure. Furthermore the diester prodrugs of cilazaprilate possess all the properties necessary to be topically administered, preferably via transdermal therapeutic systems.

Abstract: The present invention relates to diester prodrugs of cilazaprilate which undergo enzymatic cleavage to release the active metabolite cilazaprilate that is used for the treatment of hypertension and congestive heart failure. Furthermore the diester prodrugs of cilazaprilate possess all the properties necessary to be topically administered, preferably via transdermal therapeutic systems.

Abstract: The present invention relates to particular esters of bendamustine and related compounds, and medical uses thereof.

Abstract: The invention relates to the release of singlet oxygen by thermally activated decomposition of aromatic endoperoxide molecules in material systems [e.g. polymer (nano) particles or polymer films]. Due to the short lifespan and diffusion length of singlet oxygen, the technical problem is that the majority of the decomposition may only take place if the singlet oxygen molecules can reach the target region. For example, either the penetration of the polymer particles into the cancer cells to be killed, or the settlement of bacteria on an implant coated with the polymer film, must be accomplished. It is necessary to allow adaptation of the time progression of the decomposition for the application. The adaptation is performed by chemically and/or physically modifying the functional structures present in the material system, each made of the molecule forming the endoperoxide and at least one adjacent molecule or the cage formed by all adjacent molecules.

Abstract: The invention relates to novel, water-soluble porphyrin platinum compounds of the tetraarylporphyrin platinum derivatives type or of the hematoporphyrin platinum derivatives type with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases. In particular, the compounds are suitable for photodynamic anti-tumor therapy.

Abstract: The invention relates to novel, water-soluble porphyrin platinum compounds of the tetraarylporphyrin platinum derivatives type or of the hematoporphyrin platinum derivatives type with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases. In particular, the compounds are suitable for photodynamic anti-tumor therapy.

Abstract: The invention relates to a process for preparing N,N'-disubstituted p-quinonediimines of general formula I ##STR1## wherein a corresponding N,N'-disubstituted p-phenylenediamine is oxidized in alkaline/alcoholic solution, and also their use. The invention further provides organosilanes containing methacryloxy or acryloxy groups and having general formula II ##STR2## where R.sup.3 is a hydrogen atom or a methyl group and R.sup.4 and R.sup.5 are identical or different alkyl groups having from 1 to 4 carbon atoms and m is equal to 0 or 1 or 2, which organosilanes contain N,N'-disubstituted p-quinonediimines. Processes for preparing and stabilizing organosilanes of general formula II are described.

Abstract: The present invention relates to water-containing solutions of acrylic-functionalized organosilanes of the general formula I ##STR1## in which R is a methyl or ethyl group, having a starting-material concentration of organosilane of between 10 and 80% by weight. The present invention additionally relates to a process for the preparation of such water-containing solutions of acrylic-functionalized organosilanes and to their use, inter alia for coatings, surfaces or intermediate layers, which are obtainable by applying organosilane-containing compounds from a solution to a surface and by crosslinking by means of UV light.

Abstract: The invention relates to a process for preparing N,N'-disubstituted p-quinonediimines of general formula I ##STR1## wherein a corresponding N,N'-disubstituted p-phenylenediamine is oxidized in alkaline/alcoholic solution, and also their use. The invention further provides organosilanes containing methacryloxy or acryloxy groups and having general formula II ##STR2## where R.sup.3 is a hydrogen atom or a methyl group and R.sup.4 and R.sup.5 are identical or different alkyl groups having from 1 to 4 carbon atoms and m is equal to 0 or 1 or 2, which organosilanes contain N,N'-disubstituted p-quinonediimines. Processes for preparing and stabilizing organosilanes of general formula II are described.

Abstract: Acryloyloxypropylalkoxysilane compositions containing one or more acryloyloxypropylalkoxysilanes of the formula ##STR1## wherein R.sup.1 and R.sup.2 are, independently, identical or different alkyl groups having 1 to 4 carbon atoms, m is an integer from 0 to 2 and R is hydrogen or a methyl group, and an amount of one or more tertiary amines sufficient to provide a pH higher than the intrinsic pH of the acryloyloxypropylalkoxysilane itself and to improve shelf storage, a process for their preparation, and to their use in preparing silicon-containing coating materials and paints.

Abstract: Disclosed is a casting resin based on acrylic acid esters having a high content of finely dispersed fillers and containing a mixture of organosilicon compounds having functional groups and metallic acid esters of metals of Groups IVB and VB of the Periodic Table of the Elements. The functional group of the organosilicon compound is ethylenically unsaturated and bound to the silicon atom either directly or through alkylene groups. The addition of this mixture to the casing resins produces a desirable reduction of the viscosity of these resins, which are used, for example, for the manufacture of sanitary articles.The filler content is at least 20% and can be as high as 95% with the proviso that when the filler content is in excess of 80 wt. -%, the filler contains 10 to 30 wt. -%, based on the total weight of filler, of fines having a particle size less than 0.1 mm and the remainder of the filler being coarse up to 4 mm.